Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  RHÖN-KLINIKUM Aktiengesellschaft    RHK   DE0007042301

RHÖN-KLINIKUM AKTIENGESELLSCHAFT

(RHK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
Strengths
  • The share is getting closer to its long-term support in weekly data, at EUR 15.8, which offers good timing for buyers.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
  • The company sustains low margins.
  • The firm trades with high earnings multiples: 32.4 times its 2020 earnings per share.
Ratings chart
Sector Healthcare Facilities & Services - NEC
1st jan.Capitalisation (M$)Investor Rating
RHÖN-KLINIKUM AKTIENGESELLS..-5.84%1 304
CVS HEALTH CORPORATION-18.90%78 849
HCA HEALTHCARE, INC.-7.59%46 172
FRESENIUS MEDICAL CARE AG &..4.06%23 792
LABORATORY CORPORATION OF A..22.65%20 210
QUEST DIAGNOSTICS19.05%17 074
PING AN HEALTHCARE AND TECH..75.90%14 804
UNIVERSAL HEALTH SERVICES-19.43%9 819
DAVITA INC.21.35%9 652
MEINIAN ONEHEALTH HEALTHCAR..1.14%8 762
CHEMED CORPORATION11.24%7 779
ENCOMPASS HEALTH CORPORATIO..-2.71%6 702
WINNING HEALTH TECHNOLOGY G..66.45%6 121
RYMAN HEALTHCARE LIMITED-9.74%4 889
DIAN DIAGNOSTICS GROUP CO.,..72.53%3 543
AMN HEALTHCARE SERVICES, IN..6.74%3 125
More Results
Financials
Sales 2020 1 354 M 1 602 M 1 602 M
Net income 2020 34,3 M 40,6 M 40,6 M
Net Debt 2020 - - -
P/E ratio 2020 32,4x
Yield 2020 1,82%
Capitalization 1 102 M 1 304 M 1 304 M
Capi. / Sales 2020 0,81x
Capi. / Sales 2021 0,77x
Nbr of Employees 18 131
Free-Float 6,59%
Upcoming event on RHÖN-KLINIKUM AKTIENGESELLSCHAFT
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus -
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes